The treatment of benign prostatic hyperplasia (BPH) that causes lower urinary tract symptoms has advanced enormously since the days when it was a simple choice between no treatment with ...

Enlarged prostate is a common health issue for men over 50, causing urinary problems due to prostate enlargement compressing the urinary passage. Early consultation with a urologist is crucial for ...

Comparison of laparoscopic radiofrequency ablation with percutaneous radiofrequency ablation in the treatment of chronic hepatitis B-related hepatocellular carcinoma involving specific sites: A ...

Benign prostatic hyperplasia (BPH) is when the prostate and surrounding tissue expands. The prostate goes through two main growth periods as a man ages. The first is early in puberty when the prostate ...

The Georgetown Public Hospital Corporation (GPHC) is now the first healthcare institution in the southern Caribbean to have acquired advanced technology to conduct laser treatment of enlarged prostate ...

As men get older, their risk for developing an enlarged prostate gland increases. This condition, known as Benign Prostatic Hyperplasia, or BPH, affects about half of men between the ages of 51 and 60 ...

In its one decade of operations, Vistara made a mark for its product and service quality as India’s foremost full-service carrier, setting itself apart in a market dominated by no-frills airlines. The ...

Literature about prostate cancer in transgender women is growing, but many questions remain unanswered. Unique challenges exist in the identification of transgender women that can slow or even ...

Benign moles have the potential to develop into a type of skin cancer called melanoma. Moles are benign tumors formed from melanocytes (cells in the skin that make the pigment melanin). Moles come in ...

Identifying moles vs. skin cancer is not always easy. However, there are telltale signs that can help differentiate a benign (non-cancerous) skin lesion from potentially dangerous skin cancer. Benign ...

The decision comes after a pre-specified futility analysis determined that it was unlikely that the study would meet its primary end point.

PARP Inhibitors in Metastatic Prostate Cancer: Efficacy, Trials, and Combination Therapies ...